Literature DB >> 15387965

[The effects of the active constituents of Alisma orientalis on renal stone formation and bikunin expression in rat urolithiasis model].

Zheng-guo Cao1, Ji-hong Liu, Si-wei Zhou, Wei Wu, Chun-ping Yin, Ji-zhou Wu.   

Abstract

OBJECTIVE: To evaluate the effects of the active constituents of Alisma orientalis on the expression of bikunin mRNA in rat urolithiasis model, and explore the mechanism of this traditional Chinese medicine on prevention of urinary calculi.
METHODS: Modern phytochemistry and bioactivity guided isolation techniques were applied to extract the active constituents of Alisma orientalis. Hyperoxaluria and the renal oxalate calcium stone formation were induced in rats by infusion into the stomach with 1% ethylene glycol and 2% ammonium chloride. 30 adult male Wistar rats were randomized into 3 groups of 10 rats: control group, infused into the stomach with running water; stone-forming group, infused into the stomach with 1% ethylene glycol and 2% ammonium chloride so as to make into renal oxalate calcium stone model; and group of Alisma orientalis, infused into the stomach with 2% ammonium chloride and the constituents of Alisma orientalis. Four weeks after the rats were killed and their kidneys were taken out. Reverse transcription polymerase chain reaction technique was used to examine the bikunin mRNA expression levels in the rat renal tissues. The calcium oxalate deposits in the kidneys were detected by microscopy. The serum creatinnine and blood urea nitrogen levels, renal tissue calcium content, 24 h urinary calcium and oxalate excretion were also detected.
RESULTS: In the group administered with the active constituents of Alisma orientalis, calcium oxalate deposits in the kidney, serum creatinnine and blood urea nitrogen levels, the bikunin mRNA expression levels, renal tissue calcium content and 24 h urinary calcium excretion were all significantly lower than those in the model group (the bikunin mRNA expression levels: 0.53 +/- 0.17 vs 0.71 +/- 0.25, P < 0.05; renal tissue calcium content: 4.70 mg/g +/- 0.08 mg/g vs 9.49 mg/g +/- 0.45 mg/g, P < 0.01; 24 h urinary calcium excretion: 37 micromol +/- 2 micromol vs 62 micromol +/- 2 micromol, P < 0.01).
CONCLUSION: The active constituents of Alisma orientalis can down-regulate the bikunin mRNA expression, decrease the calcium oxalate formation in rat kidney, and inhibit the renal stone formation in rat urolithiasis model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15387965

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  5 in total

1.  Protective effect of Flos carthami extract against ethylene glycol-induced urolithiasis in rats.

Authors:  Wu-Chou Lin; Ming-Tsung Lai; Huey-Yi Chen; Chien-Yi Ho; Kee-Ming Man; Jui-Lung Shen; Yuan-Ju Lee; Fuu-Jen Tsai; Yung-Hsiang Chen; Wen-Chi Chen
Journal:  Urol Res       Date:  2012-03-08

2.  Antilithic effects of extracts from different polarity fractions of Desmodium styracifolium on experimentally induced urolithiasis in rats.

Authors:  Songtao Xiang; Jianfu Zhou; Jing Li; Qian Wang; Qiuhong Zhang; Zhongxiang Zhao; Lei Zhang; Zhiqiang Chen; Shusheng Wang
Journal:  Urolithiasis       Date:  2015-06-30       Impact factor: 3.436

3.  Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis - a prospective randomized controlled trial.

Authors:  Eugene Lin; Lin Ho; Mao-Sheng Lin; Min-Ho Huang; Wen-Chi Chen
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-08-12

4.  A traditional Chinese herbal antilithic formula, Wulingsan, effectively prevents the renal deposition of calcium oxalate crystal in ethylene glycol-fed rats.

Authors:  Chou-Huang Tsai; Yu-Cheng Chen; Lieh-Der Chen; Tien-Chien Pan; Chien-Yi Ho; Ming-Tsung Lai; Fuu-Jen Tsai; Wen-Chi Chen
Journal:  Urol Res       Date:  2007-11-27

5.  Therapeutic Effect of the Tuber of Alisma orientale on Lipopolysaccharide-Induced Acute Lung Injury.

Authors:  Kyun Ha Kim; Min Jung Kwun; Jun-Yong Choi; Kyung-Seop Ahn; Sei-Ryang Oh; Yong Gyu Lee; John W Christman; Ruxana T Sadikot; Chang Woo Han; Myungsoo Joo
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-25       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.